The activated serine protease factor Xa is a promising target for new anticoagulants. After
studies on naturally occurring factor Xa inhibitors indicated that such agents could be …

Although results of some phase III clinical trials of new oral anticoagulants are now known, it
is important to understand the mechanisms of their actions. These new agents exert their …

Anticoagulants are recommended for the prevention and treatment of a wide variety of
thromboembolic events. Although existing anticoagulants are effective, their use is limited by …

Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the
blood coagulation pathway leading to thrombin generation and clot formation. It is selective …

There are several novel anticoagulants in development that target factor Xa (FXa)-the pivotal
point of the coagulation cascade. One promising agent is rivaroxaban (a highly selective …

Rivaroxaban, an oral, direct factor Xa inhibitor, is a small molecule drug capable of inhibiting
not only free factor Xa with high selectivity but also prothrombinase‐bound and clot …

Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for
many decades. Although effective, warfarin has numerous limitations, including a variable …

Purpose. The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in
clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban …

Rivaroxaban (BAY 59‐7939) is an oral, direct Factor Xa inhibitor in advanced clinical
development for the prevention and treatment of thromboembolic disorders. This was a …

Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa
and Factor Xa in the prothrombinase complex. It is absorbed rapidly, with maximum plasma …